<code id='886A07FE77'></code><style id='886A07FE77'></style>
    • <acronym id='886A07FE77'></acronym>
      <center id='886A07FE77'><center id='886A07FE77'><tfoot id='886A07FE77'></tfoot></center><abbr id='886A07FE77'><dir id='886A07FE77'><tfoot id='886A07FE77'></tfoot><noframes id='886A07FE77'>

    • <optgroup id='886A07FE77'><strike id='886A07FE77'><sup id='886A07FE77'></sup></strike><code id='886A07FE77'></code></optgroup>
        1. <b id='886A07FE77'><label id='886A07FE77'><select id='886A07FE77'><dt id='886A07FE77'><span id='886A07FE77'></span></dt></select></label></b><u id='886A07FE77'></u>
          <i id='886A07FE77'><strike id='886A07FE77'><tt id='886A07FE77'><pre id='886A07FE77'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot